obiadminpharma
Resignation of representative of corporate director
Date of occurrence of the change: Jul 13, 2020 Name of legal person: Sheng Chen Investment Co. Ltd. Name and resume of the previous position holder: Lung-Yeh Cho / Special …
OBI filled application of Phase 1 human clinical study for active immunotherapeutic cancer vaccine, OBI-866, to TFDA
Date of occurrence of the event: Jun 29, 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: Not …
Supplementary statements on news article
Date of occurrence of the event: Jun 23, 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): head office Reciprocal shareholding ratios: Not …
Poster Presentations at AACR 2020 Virtual Annual Meeting II
Session PO ET04.02 Identification of molecular targets 2 Title: The role of Globo H in cancer cell survival Presenter: Tzer-Min Kuo, PhD, et. al., OBI Pharma, Inc., Taipei, Taiwan Virtual …
Announcement of resolution items from 2020 Annual General Meeting
Date of the shareholders’ meeting: Jun 22, 2020 Important resolutions I. Profit distribution/deficit compensation: Resolution on acknowledgment of 2019 Deficit Compensation Important resolutions II. Amendments of the company charter: None …
Announcement of 2020 annual general meeting passes removal of the noncompete clause for directors
Date of the shareholders’ meeting resolution: Jun 22, 2020 Name and title of the managerial officer with permission to engage in competitive conduct: Director: Frank Chen (Sheng Cheng Investment Co., …
OBI Pharma Announces Poster Presentations at AACR 2020 Virtual Annual Meeting II
Poster Presentations to highlight the role of the Globo H antigen in cancer cell survival and its prevalence in different tumor types TAIPEI, Taiwan, June 16, 2020/PRNewswire/OBI Pharma, Inc. (TPEx: …
OBI filled application of Phase 1 human clinical study for Novel Botulinum Toxin preparation, OBI-858, to TFDA
OBI filled application of Phase 1 human clinical study for Novel Botulinum Toxin preparation, OBI-858, to TFDA Date of occurrence of the event: Jun 10, 2020 Company name: OBI Pharma …
OBI Pharma Posters at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424
Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk …
OBI has filed application of Phase I/II human clinical studies for passive immunotherapeutic monoclonal antibody OBI-888 to TFDA
Date of occurrence of the event: May 29, 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: Not …